Onychomycosis in Psoriatic Patients with Nail Disorders: Aetiological Agents and Immunosuppressive Therapy

Table 1

Characteristics of the psoriatic patients.

Data	Patients (n = 38)	p value
Gender		0.7
Male	18 (47.4)
Female	20 (52.6)
Psoriatic disease		0.034
Psoriasis	15 (39.5)
Psoriatic arthritis	4 (10.5)
Both	19 (50)
Duration of clinical manifestations		0.85
<1 year	0
1–4 years	4 (10.5)
5–9 years	8 (21.1)
10–29 years	22 (57.9)
>30 years	4 (10.5)
Duration nail changes		0.92
<1 year	1 (2.6)
1–4 years	10 (26.3)
5–9 years	8 (21.1)
10–29 years	15 (39.5)
>30 years	2 (5.3)
Do not know	2 (5.3)
Comorbidities		0.16
None	13 (34.2)
Systemic arterial hypertension	6 (15.8)
Hypothyroidism	1 (2.6)
Psychiatric disorder	2 (5.3)
Benign nodule in the lungs	1 (2.6)
SAH + DM	3 (7.9)
SAH + dyslipidaemia	1 (2.6)
SAH + CVI	1 (2.6)
DM + HS	1 (2.6)
Psychiatric disorder + Parkinson	1 (2.6)
SAH + DM + dyslipidaemia	3 (7.9)
SAH + DM + HS	1 (2.6)
SAH + DM + hypothyroidism	1 (2.6)
DM + GERD + megacolon	1 (2.6)
SAH + DM + dyslipidaemia + hypothyroidism	1 (2.6)
SAH + DM + dyslipidaemia + CVI	1 (2.6)
Nail manifestation		0.43
Subungual hyperkeratosis	13 (34.2)
Onycholysis	11 (28.9)
Hyperkeratosis + onycholysis	11 (28.9)
Onychodystrophy	1 (2.6)
Hyperkeratosis + onychodystrophy	1 (2.6)
Onycholysis + onychodystrophy	1 (2.6)
Site		0.88
Foot	21 (55.3)
Hand	6 (15.8)
Foot + hand	11 (28.9)

SAH: systemic arterial hypertension; DM: diabetes mellitus; CVI: chronic venous insufficiency; GERD: gastroesophageal reflux disease; HS: hepatic steatosis. Isolated or associated manifestations.